nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Piloerection—Irinotecan—colon cancer	0.0659	0.066	CcSEcCtD
Doxylamine—Miosis—Irinotecan—colon cancer	0.0274	0.0274	CcSEcCtD
Doxylamine—Lacrimation—Irinotecan—colon cancer	0.0194	0.0195	CcSEcCtD
Doxylamine—Lacrimation—Fluorouracil—colon cancer	0.0186	0.0187	CcSEcCtD
Doxylamine—Sneezing—Capecitabine—colon cancer	0.0138	0.0138	CcSEcCtD
Doxylamine—Lacrimation increased—Irinotecan—colon cancer	0.0124	0.0124	CcSEcCtD
Doxylamine—Loss of libido—Methotrexate—colon cancer	0.0123	0.0124	CcSEcCtD
Doxylamine—Lacrimation increased—Fluorouracil—colon cancer	0.0119	0.0119	CcSEcCtD
Doxylamine—Polyuria—Vincristine—colon cancer	0.0097	0.00972	CcSEcCtD
Doxylamine—Rhinorrhoea—Capecitabine—colon cancer	0.00944	0.00946	CcSEcCtD
Doxylamine—Liver disorder—Methotrexate—colon cancer	0.00836	0.00837	CcSEcCtD
Doxylamine—Lacrimation increased—Capecitabine—colon cancer	0.0083	0.00832	CcSEcCtD
Doxylamine—Urinary retention—Vincristine—colon cancer	0.0081	0.00812	CcSEcCtD
Doxylamine—Dehydration—Vincristine—colon cancer	0.00792	0.00794	CcSEcCtD
Doxylamine—Dehydration—Irinotecan—colon cancer	0.00772	0.00773	CcSEcCtD
Doxylamine—Irritability—Fluorouracil—colon cancer	0.00759	0.0076	CcSEcCtD
Doxylamine—Orthostatic hypotension—Irinotecan—colon cancer	0.00758	0.0076	CcSEcCtD
Doxylamine—Cramp muscle—Irinotecan—colon cancer	0.00747	0.00749	CcSEcCtD
Doxylamine—Nasopharyngitis—Fluorouracil—colon cancer	0.00711	0.00712	CcSEcCtD
Doxylamine—Pancreatitis—Irinotecan—colon cancer	0.00703	0.00705	CcSEcCtD
Doxylamine—Pancytopenia—Vincristine—colon cancer	0.00699	0.00701	CcSEcCtD
Doxylamine—Sweating increased—Irinotecan—colon cancer	0.00699	0.007	CcSEcCtD
Doxylamine—Depression—Vincristine—colon cancer	0.00655	0.00656	CcSEcCtD
Doxylamine—Pancytopenia—Fluorouracil—colon cancer	0.00652	0.00654	CcSEcCtD
Doxylamine—Polyuria—Capecitabine—colon cancer	0.00633	0.00634	CcSEcCtD
Doxylamine—Bone disorder—Methotrexate—colon cancer	0.00631	0.00632	CcSEcCtD
Doxylamine—Sweating—Vincristine—colon cancer	0.0063	0.00631	CcSEcCtD
Doxylamine—Haemolytic anaemia—Capecitabine—colon cancer	0.00615	0.00616	CcSEcCtD
Doxylamine—Sweating—Irinotecan—colon cancer	0.00613	0.00614	CcSEcCtD
Doxylamine—Hallucination—Vincristine—colon cancer	0.00587	0.00588	CcSEcCtD
Doxylamine—Bradycardia—Irinotecan—colon cancer	0.00584	0.00586	CcSEcCtD
Doxylamine—Urinary tract disorder—Vincristine—colon cancer	0.00582	0.00583	CcSEcCtD
Doxylamine—Urethral disorder—Vincristine—colon cancer	0.00578	0.00579	CcSEcCtD
Doxylamine—Agranulocytosis—Fluorouracil—colon cancer	0.00572	0.00573	CcSEcCtD
Doxylamine—Diplopia—Capecitabine—colon cancer	0.00555	0.00557	CcSEcCtD
Doxylamine—Cardiac disorder—Vincristine—colon cancer	0.00547	0.00548	CcSEcCtD
Doxylamine—Cardiac disorder—Irinotecan—colon cancer	0.00533	0.00534	CcSEcCtD
Doxylamine—Flushing—Irinotecan—colon cancer	0.00533	0.00534	CcSEcCtD
Doxylamine—Mediastinal disorder—Vincristine—colon cancer	0.00531	0.00532	CcSEcCtD
Doxylamine—Irritability—Capecitabine—colon cancer	0.0053	0.00531	CcSEcCtD
Doxylamine—Urinary retention—Capecitabine—colon cancer	0.00528	0.00529	CcSEcCtD
Doxylamine—Mood swings—Capecitabine—colon cancer	0.00526	0.00527	CcSEcCtD
Doxylamine—Immune system disorder—Irinotecan—colon cancer	0.00519	0.0052	CcSEcCtD
Doxylamine—Mediastinal disorder—Irinotecan—colon cancer	0.00517	0.00518	CcSEcCtD
Doxylamine—Dehydration—Capecitabine—colon cancer	0.00517	0.00518	CcSEcCtD
Doxylamine—Orthostatic hypotension—Capecitabine—colon cancer	0.00507	0.00508	CcSEcCtD
Doxylamine—Breast disorder—Capecitabine—colon cancer	0.00502	0.00503	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.005	0.00501	CcSEcCtD
Doxylamine—Nasopharyngitis—Capecitabine—colon cancer	0.00497	0.00498	CcSEcCtD
Doxylamine—Muscle spasms—Irinotecan—colon cancer	0.0048	0.00481	CcSEcCtD
Doxylamine—Erythema—Fluorouracil—colon cancer	0.00479	0.0048	CcSEcCtD
Doxylamine—Bronchospasm—Capecitabine—colon cancer	0.00472	0.00473	CcSEcCtD
Doxylamine—Agitation—Vincristine—colon cancer	0.00472	0.00473	CcSEcCtD
Doxylamine—Polyuria—Methotrexate—colon cancer	0.00471	0.00472	CcSEcCtD
Doxylamine—Sweating increased—Capecitabine—colon cancer	0.00468	0.00469	CcSEcCtD
Doxylamine—Ill-defined disorder—Irinotecan—colon cancer	0.00464	0.00465	CcSEcCtD
Doxylamine—Vertigo—Vincristine—colon cancer	0.00461	0.00462	CcSEcCtD
Doxylamine—Abdominal discomfort—Capecitabine—colon cancer	0.0046	0.00461	CcSEcCtD
Doxylamine—Leukopenia—Vincristine—colon cancer	0.00459	0.0046	CcSEcCtD
Doxylamine—Pancytopenia—Capecitabine—colon cancer	0.00456	0.00457	CcSEcCtD
Doxylamine—Malaise—Irinotecan—colon cancer	0.00451	0.00452	CcSEcCtD
Doxylamine—Vertigo—Irinotecan—colon cancer	0.00449	0.0045	CcSEcCtD
Doxylamine—Leukopenia—Irinotecan—colon cancer	0.00447	0.00448	CcSEcCtD
Doxylamine—Convulsion—Vincristine—colon cancer	0.00445	0.00446	CcSEcCtD
Doxylamine—Leukopenia—Fluorouracil—colon cancer	0.00428	0.00429	CcSEcCtD
Doxylamine—Depression—Capecitabine—colon cancer	0.00427	0.00428	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.00424	0.00425	CcSEcCtD
Doxylamine—Discomfort—Irinotecan—colon cancer	0.0042	0.00421	CcSEcCtD
Doxylamine—Anaphylactic shock—Vincristine—colon cancer	0.00419	0.0042	CcSEcCtD
Doxylamine—Convulsion—Fluorouracil—colon cancer	0.00415	0.00416	CcSEcCtD
Doxylamine—Confusional state—Irinotecan—colon cancer	0.00411	0.00412	CcSEcCtD
Doxylamine—Nervous system disorder—Vincristine—colon cancer	0.00411	0.00412	CcSEcCtD
Doxylamine—Thrombocytopenia—Vincristine—colon cancer	0.0041	0.00411	CcSEcCtD
Doxylamine—Anaphylactic shock—Irinotecan—colon cancer	0.00408	0.00409	CcSEcCtD
Doxylamine—Hyperhidrosis—Vincristine—colon cancer	0.00405	0.00406	CcSEcCtD
Doxylamine—Discomfort—Fluorouracil—colon cancer	0.00403	0.00403	CcSEcCtD
Doxylamine—Nervous system disorder—Irinotecan—colon cancer	0.004	0.00401	CcSEcCtD
Doxylamine—Agranulocytosis—Capecitabine—colon cancer	0.00399	0.004	CcSEcCtD
Doxylamine—Thrombocytopenia—Irinotecan—colon cancer	0.00399	0.004	CcSEcCtD
Doxylamine—Anorexia—Vincristine—colon cancer	0.00399	0.004	CcSEcCtD
Doxylamine—Irritability—Methotrexate—colon cancer	0.00395	0.00395	CcSEcCtD
Doxylamine—Hyperhidrosis—Irinotecan—colon cancer	0.00394	0.00395	CcSEcCtD
Doxylamine—Confusional state—Fluorouracil—colon cancer	0.00394	0.00395	CcSEcCtD
Doxylamine—Mood swings—Methotrexate—colon cancer	0.00392	0.00392	CcSEcCtD
Doxylamine—Hypotension—Vincristine—colon cancer	0.00391	0.00392	CcSEcCtD
Doxylamine—Bradycardia—Capecitabine—colon cancer	0.00391	0.00392	CcSEcCtD
Doxylamine—Anaphylactic shock—Fluorouracil—colon cancer	0.00391	0.00391	CcSEcCtD
Doxylamine—Anorexia—Irinotecan—colon cancer	0.00389	0.0039	CcSEcCtD
Doxylamine—Hepatitis—Capecitabine—colon cancer	0.00384	0.00385	CcSEcCtD
Doxylamine—Nervous system disorder—Fluorouracil—colon cancer	0.00383	0.00384	CcSEcCtD
Doxylamine—Thrombocytopenia—Fluorouracil—colon cancer	0.00382	0.00383	CcSEcCtD
Doxylamine—Tachycardia—Fluorouracil—colon cancer	0.00381	0.00382	CcSEcCtD
Doxylamine—Hypotension—Irinotecan—colon cancer	0.00381	0.00382	CcSEcCtD
Doxylamine—Urinary tract disorder—Capecitabine—colon cancer	0.00379	0.0038	CcSEcCtD
Doxylamine—Insomnia—Vincristine—colon cancer	0.00379	0.0038	CcSEcCtD
Doxylamine—Urethral disorder—Capecitabine—colon cancer	0.00377	0.00377	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—colon cancer	0.00374	0.00374	CcSEcCtD
Doxylamine—Anorexia—Fluorouracil—colon cancer	0.00372	0.00373	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00372	0.00373	CcSEcCtD
Doxylamine—Insomnia—Irinotecan—colon cancer	0.00369	0.0037	CcSEcCtD
Doxylamine—Hypotension—Fluorouracil—colon cancer	0.00365	0.00366	CcSEcCtD
Doxylamine—Decreased appetite—Vincristine—colon cancer	0.00364	0.00365	CcSEcCtD
Doxylamine—Dyspnoea—Irinotecan—colon cancer	0.00364	0.00364	CcSEcCtD
Doxylamine—Erythema multiforme—Capecitabine—colon cancer	0.00363	0.00364	CcSEcCtD
Doxylamine—Somnolence—Irinotecan—colon cancer	0.00363	0.00363	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Vincristine—colon cancer	0.00362	0.00362	CcSEcCtD
Doxylamine—Fatigue—Vincristine—colon cancer	0.00361	0.00362	CcSEcCtD
Doxylamine—Eye disorder—Capecitabine—colon cancer	0.00359	0.0036	CcSEcCtD
Doxylamine—Constipation—Vincristine—colon cancer	0.00358	0.00359	CcSEcCtD
Doxylamine—Cardiac disorder—Capecitabine—colon cancer	0.00357	0.00357	CcSEcCtD
Doxylamine—Flushing—Capecitabine—colon cancer	0.00357	0.00357	CcSEcCtD
Doxylamine—Decreased appetite—Irinotecan—colon cancer	0.00355	0.00355	CcSEcCtD
Doxylamine—Insomnia—Fluorouracil—colon cancer	0.00353	0.00354	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Irinotecan—colon cancer	0.00352	0.00353	CcSEcCtD
Doxylamine—Fatigue—Irinotecan—colon cancer	0.00352	0.00352	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—colon cancer	0.0035	0.00351	CcSEcCtD
Doxylamine—Constipation—Irinotecan—colon cancer	0.00349	0.0035	CcSEcCtD
Doxylamine—Dyspnoea—Fluorouracil—colon cancer	0.00348	0.00349	CcSEcCtD
Doxylamine—Somnolence—Fluorouracil—colon cancer	0.00347	0.00348	CcSEcCtD
Doxylamine—Immune system disorder—Capecitabine—colon cancer	0.00347	0.00348	CcSEcCtD
Doxylamine—Mediastinal disorder—Capecitabine—colon cancer	0.00346	0.00347	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—colon cancer	0.00343	0.00343	CcSEcCtD
Doxylamine—Decreased appetite—Fluorouracil—colon cancer	0.0034	0.0034	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—colon cancer	0.00339	0.0034	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00337	0.00338	CcSEcCtD
Doxylamine—Feeling abnormal—Irinotecan—colon cancer	0.00336	0.00337	CcSEcCtD
Doxylamine—Erythema—Capecitabine—colon cancer	0.00334	0.00335	CcSEcCtD
Doxylamine—Feeling abnormal—Fluorouracil—colon cancer	0.00322	0.00323	CcSEcCtD
Doxylamine—Muscle spasms—Capecitabine—colon cancer	0.00322	0.00322	CcSEcCtD
Doxylamine—Drowsiness—Methotrexate—colon cancer	0.00319	0.00319	CcSEcCtD
Doxylamine—Depression—Methotrexate—colon cancer	0.00318	0.00318	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.00316	0.00317	CcSEcCtD
Doxylamine—Tremor—Capecitabine—colon cancer	0.00313	0.00314	CcSEcCtD
Doxylamine—Ill-defined disorder—Capecitabine—colon cancer	0.0031	0.00311	CcSEcCtD
Doxylamine—Urticaria—Fluorouracil—colon cancer	0.0031	0.00311	CcSEcCtD
Doxylamine—Hypersensitivity—Vincristine—colon cancer	0.00309	0.00309	CcSEcCtD
Doxylamine—Sweating—Methotrexate—colon cancer	0.00305	0.00306	CcSEcCtD
Doxylamine—Malaise—Capecitabine—colon cancer	0.00302	0.00302	CcSEcCtD
Doxylamine—Vertigo—Capecitabine—colon cancer	0.00301	0.00301	CcSEcCtD
Doxylamine—Hypersensitivity—Irinotecan—colon cancer	0.003	0.00301	CcSEcCtD
Doxylamine—Asthenia—Vincristine—colon cancer	0.003	0.00301	CcSEcCtD
Doxylamine—Leukopenia—Capecitabine—colon cancer	0.00299	0.003	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—colon cancer	0.00297	0.00298	CcSEcCtD
Doxylamine—Palpitations—Capecitabine—colon cancer	0.00296	0.00296	CcSEcCtD
Doxylamine—Asthenia—Irinotecan—colon cancer	0.00293	0.00293	CcSEcCtD
Doxylamine—Hypersensitivity—Fluorouracil—colon cancer	0.00288	0.00288	CcSEcCtD
Doxylamine—Diarrhoea—Vincristine—colon cancer	0.00287	0.00287	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—colon cancer	0.00286	0.00287	CcSEcCtD
Doxylamine—Anxiety—Capecitabine—colon cancer	0.00284	0.00284	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—colon cancer	0.00282	0.00283	CcSEcCtD
Doxylamine—Discomfort—Capecitabine—colon cancer	0.00281	0.00282	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—colon cancer	0.0028	0.00281	CcSEcCtD
Doxylamine—Diarrhoea—Irinotecan—colon cancer	0.00279	0.0028	CcSEcCtD
Doxylamine—Dry mouth—Capecitabine—colon cancer	0.00278	0.00279	CcSEcCtD
Doxylamine—Dizziness—Vincristine—colon cancer	0.00277	0.00278	CcSEcCtD
Doxylamine—Pruritus—Fluorouracil—colon cancer	0.00276	0.00277	CcSEcCtD
Doxylamine—Confusional state—Capecitabine—colon cancer	0.00275	0.00276	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—colon cancer	0.0027	0.00271	CcSEcCtD
Doxylamine—Dizziness—Irinotecan—colon cancer	0.0027	0.0027	CcSEcCtD
Doxylamine—Nervous system disorder—Capecitabine—colon cancer	0.00268	0.00268	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—colon cancer	0.00267	0.00268	CcSEcCtD
Doxylamine—Diarrhoea—Fluorouracil—colon cancer	0.00267	0.00268	CcSEcCtD
Doxylamine—Thrombocytopenia—Capecitabine—colon cancer	0.00267	0.00268	CcSEcCtD
Doxylamine—Tachycardia—Capecitabine—colon cancer	0.00266	0.00267	CcSEcCtD
Doxylamine—Vomiting—Vincristine—colon cancer	0.00266	0.00267	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—colon cancer	0.00265	0.00266	CcSEcCtD
Doxylamine—Rash—Vincristine—colon cancer	0.00264	0.00265	CcSEcCtD
Doxylamine—Hyperhidrosis—Capecitabine—colon cancer	0.00264	0.00264	CcSEcCtD
Doxylamine—Dermatitis—Vincristine—colon cancer	0.00264	0.00264	CcSEcCtD
Doxylamine—Anorexia—Capecitabine—colon cancer	0.0026	0.00261	CcSEcCtD
Doxylamine—Vomiting—Irinotecan—colon cancer	0.00259	0.0026	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—colon cancer	0.00258	0.00259	CcSEcCtD
Doxylamine—Dizziness—Fluorouracil—colon cancer	0.00258	0.00259	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—colon cancer	0.00258	0.00258	CcSEcCtD
Doxylamine—Rash—Irinotecan—colon cancer	0.00257	0.00258	CcSEcCtD
Doxylamine—Dermatitis—Irinotecan—colon cancer	0.00257	0.00257	CcSEcCtD
Doxylamine—Hypotension—Capecitabine—colon cancer	0.00255	0.00256	CcSEcCtD
Doxylamine—Erythema—Methotrexate—colon cancer	0.00249	0.0025	CcSEcCtD
Doxylamine—Nausea—Vincristine—colon cancer	0.00249	0.00249	CcSEcCtD
Doxylamine—Vomiting—Fluorouracil—colon cancer	0.00248	0.00249	CcSEcCtD
Doxylamine—Insomnia—Capecitabine—colon cancer	0.00247	0.00247	CcSEcCtD
Doxylamine—Rash—Fluorouracil—colon cancer	0.00246	0.00247	CcSEcCtD
Doxylamine—Dermatitis—Fluorouracil—colon cancer	0.00246	0.00247	CcSEcCtD
Doxylamine—Dyspnoea—Capecitabine—colon cancer	0.00243	0.00244	CcSEcCtD
Doxylamine—Nausea—Irinotecan—colon cancer	0.00242	0.00243	CcSEcCtD
Doxylamine—Decreased appetite—Capecitabine—colon cancer	0.00237	0.00238	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Capecitabine—colon cancer	0.00236	0.00236	CcSEcCtD
Doxylamine—Fatigue—Capecitabine—colon cancer	0.00235	0.00236	CcSEcCtD
Doxylamine—Constipation—Capecitabine—colon cancer	0.00233	0.00234	CcSEcCtD
Doxylamine—Nausea—Fluorouracil—colon cancer	0.00232	0.00233	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—colon cancer	0.00231	0.00232	CcSEcCtD
Doxylamine—Feeling abnormal—Capecitabine—colon cancer	0.00225	0.00225	CcSEcCtD
Doxylamine—Malaise—Methotrexate—colon cancer	0.00225	0.00225	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—colon cancer	0.00224	0.00224	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—colon cancer	0.00223	0.00223	CcSEcCtD
Doxylamine—Urticaria—Capecitabine—colon cancer	0.00217	0.00217	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—colon cancer	0.00216	0.00216	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—colon cancer	0.00209	0.0021	CcSEcCtD
Doxylamine—Confusional state—Methotrexate—colon cancer	0.00205	0.00205	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—colon cancer	0.00203	0.00204	CcSEcCtD
Doxylamine—Hypersensitivity—Capecitabine—colon cancer	0.00201	0.00202	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—colon cancer	0.00199	0.002	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—colon cancer	0.00199	0.00199	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—colon cancer	0.00196	0.00197	CcSEcCtD
Doxylamine—Asthenia—Capecitabine—colon cancer	0.00196	0.00196	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—colon cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Pruritus—Capecitabine—colon cancer	0.00193	0.00194	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—colon cancer	0.0019	0.0019	CcSEcCtD
Doxylamine—Diarrhoea—Capecitabine—colon cancer	0.00187	0.00187	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—colon cancer	0.00184	0.00184	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—colon cancer	0.00181	0.00182	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—colon cancer	0.00181	0.00181	CcSEcCtD
Doxylamine—Dizziness—Capecitabine—colon cancer	0.00181	0.00181	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—colon cancer	0.00177	0.00177	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—colon cancer	0.00175	0.00176	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—colon cancer	0.00175	0.00176	CcSEcCtD
Doxylamine—Vomiting—Capecitabine—colon cancer	0.00174	0.00174	CcSEcCtD
Doxylamine—Rash—Capecitabine—colon cancer	0.00172	0.00172	CcSEcCtD
Doxylamine—Dermatitis—Capecitabine—colon cancer	0.00172	0.00172	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—colon cancer	0.00167	0.00168	CcSEcCtD
Doxylamine—Nausea—Capecitabine—colon cancer	0.00162	0.00162	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—colon cancer	0.00161	0.00162	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—colon cancer	0.0015	0.0015	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—colon cancer	0.00146	0.00146	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—colon cancer	0.00144	0.00144	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—colon cancer	0.00139	0.00139	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—colon cancer	0.00134	0.00135	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—colon cancer	0.00129	0.00129	CcSEcCtD
Doxylamine—Rash—Methotrexate—colon cancer	0.00128	0.00128	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—colon cancer	0.00128	0.00128	CcSEcCtD
Doxylamine—Nausea—Methotrexate—colon cancer	0.00121	0.00121	CcSEcCtD
Doxylamine—Toremifene—ABCB1—colon cancer	0.000745	0.356	CrCbGaD
Doxylamine—Tamoxifen—ABCB1—colon cancer	0.000298	0.142	CrCbGaD
Doxylamine—Doxepin—ABCB1—colon cancer	0.000297	0.142	CrCbGaD
Doxylamine—Methadone—ABCB1—colon cancer	0.000295	0.141	CrCbGaD
Doxylamine—Imipramine—ABCB1—colon cancer	0.000231	0.11	CrCbGaD
Doxylamine—Amitriptyline—ABCB1—colon cancer	0.000229	0.11	CrCbGaD
